NCT03859206

Brief Summary

Pleural empyema : is a collection of pus in the pleural cavity caused by microorganisms, usually bacteria.\[1\] Medical thoracoscopy has played a marginal role in the treatment of empyema for a long time, but has become more and more established in recent years. It can be per-formed in analgo-sedation in a bronchoscopy suite. It is minimally invasive and costs are much lower compared to surgical VATS. The diagnostic and therapeutic power seems to be comparable to VATS, since several studies show success rates with medical thoracoscopy between 73 and 100% (2, 3) .

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2019

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 19, 2019

Completed
10 days until next milestone

First Posted

Study publicly available on registry

March 1, 2019

Completed
Same day until next milestone

Study Start

First participant enrolled

March 1, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2021

Completed
Last Updated

March 5, 2019

Status Verified

March 1, 2019

Enrollment Period

2 years

First QC Date

February 19, 2019

Last Update Submit

March 1, 2019

Conditions

Keywords

medicalThoracoscopyloculatedempyema

Outcome Measures

Primary Outcomes (1)

  • Medical cure without secondary Intervention

    medical cure will be defined as radiologic confirmation of successful pleural drainage (i.e. reduction of the size of the pleural fluid on the chest X-ray and chest ultrasound )with no need for further treatment by r surgical interventions) objective evidence of sepsis resolution (improvement in temperature and clinical condition and decreasing inflammatory laboratory markers .and decrease of amount of fluid discharge less than (50-100)cc per day .

    up to 14 days .

Secondary Outcomes (2)

  • Duration of hospital stay

    up to 14 day .

  • Adverse events

    within 24 hour after medical thoracoscopy

Study Arms (2)

empyema patients having medical thoracoscopy

EXPERIMENTAL

patients having empyema will undergo medical thoracoscopy as follow : With the closed biopsy forceps, step by step, fibrinous septae will be perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken \& If no lesion, biopsy from parietal pleura was obtained from any sites. the intervention : is breaking the septation within the loculated empyema

Other: Medical thoracoscopy

tube thoracostomy in patients with empyema

NO INTERVENTION

after confirmation of diagnosis of empyema Following , a chest tube (gauge 26-28) will be introduced and connected to underwater seal. The wound was then closed around the tube by stitches to fix it in position.

Interventions

• With the closed biopsy forceps, step by step, fibrinous septae were perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken \& If no lesion, biopsy from parietal pleura was obtained from any sites.

empyema patients having medical thoracoscopy

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • unilateral or bilateral frank pleural empyema (pus) .
  • age \> 18 and \<70 years old

You may not qualify if:

  • Transudative pleural effusion.
  • Bleeding disorders.
  • Hemo-dynamically unstable patients.
  • General contraindications to thoracoscopy e.g. unstable angina, left ventricular failure, uncontrolled hypertension, bleeding tendency. . .etc.
  • Recent history of chest trauma or proved hemothorax.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Redden MD, Chin TY, van Driel ML. Surgical versus non-surgical management for pleural empyema. Cochrane Database Syst Rev. 2017 Mar 17;3(3):CD010651. doi: 10.1002/14651858.CD010651.pub2.

    PMID: 28304084BACKGROUND
  • Brutsche MH, Tassi GF, Gyorik S, Gokcimen M, Renard C, Marchetti GP, Tschopp JM. Treatment of sonographically stratified multiloculated thoracic empyema by medical thoracoscopy. Chest. 2005 Nov;128(5):3303-9. doi: 10.1378/chest.128.5.3303.

    PMID: 16304276BACKGROUND

MeSH Terms

Conditions

Empyema

Condition Hierarchy (Ancestors)

SuppurationInfectionsInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

shahenda mohammed gamal el din, MD

CONTACT

Mohamed M.Reda Abdelaziz, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant lecturer , chest department and tuberculosis

Study Record Dates

First Submitted

February 19, 2019

First Posted

March 1, 2019

Study Start

March 1, 2019

Primary Completion

March 1, 2021

Study Completion

May 1, 2021

Last Updated

March 5, 2019

Record last verified: 2019-03